Washington, DC (February 2, 2017) – The Pharmaceutical Research and Manufacturers of America (PhRMA) today announced that PhRMA Senior Vice President Scott LaGanga has been named head of PhRMA state advocacy and assumes the responsibilities of Jeff Bond, who announced his retirement from PhRMA. Shannon Graham has been promoted to senior vice president and will lead PhRMA’s advocacy and strategic alliances program.
“Jeff’s retirement from PhRMA comes after a remarkable 40 year career where he has served as a tireless advocate and seen us through some of the toughest challenges our industry has ever faced,” said Stephen J. Ubl, president and chief executive officer of PhRMA. “On behalf of our member companies and our entire staff, I want to thank Jeff for his tremendous commitment to PhRMA, our industry and the patients we serve.
Scott LaGanga assumes his new role after nearly ten years at PhRMA, most recently leading its third-party stakeholder relations, which includes outreach to patient groups, health care providers, business leaders, organized labor, venture capital and academic institutions. Formerly, LaGanga was executive director and co-founder of the Property Rights Alliance, a Washington, D.C.-based advocacy organization dedicated to the protection of physical and intellectual property rights, and worked for many years with Americans for Tax Reform to help ensure that U.S. tax policy allows opportunity for innovation. He is a member of the board of the Pharmaceutical Industry Labor Management Association (PILMA).
“Scott has a proven track record of leading cross-disciplinary teams at the federal and state levels,” Ubl said. “I look forward to him leveraging this experience and the power of our state advocacy organization to lead us through some of the most important work we have to do.”
Shannon Graham rises to her new role after eight years managing the strategic development and implementation of PhRMA’s federal and state-based initiatives. Prior to her current role with PhRMA, Graham was manager of state advocacy and alliance development for GlaxoSmithKline (GSK), where she collaborated with colleagues across the country to help broaden partnerships and community impact.
“Shannon’s proven ability to develop relationships and cultivate new partnerships with patient advocates and other health care groups makes her the perfect person to take on this new role,” Ubl said. “She leads a talented team that excels at one of PhRMA’s most critical functions.”
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives. Since 2000, PhRMA member companies have invested more than half a trillion dollars in the search for new treatments and cures, including an estimated $58.8 billion in 2015 alone.